Propanc Biopharma, Inc. (OTCMKTS:PPCB) Sees Large Increase in Short Interest

Propanc Biopharma, Inc. (OTCMKTS:PPCB) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 200 shares, an increase of 100.0% from the February 28th total of 100 shares. Based on an average daily trading volume, of 400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company’s shares are short sold.

Propanc Biopharma Stock Performance

PPCB traded down $0.43 during trading on Friday, reaching $5.25. 116 shares of the stock traded hands, compared to its average volume of 415. The stock’s 50-day moving average is $6.64 and its 200 day moving average is $2.31. Propanc Biopharma has a 12 month low of $2.76 and a 12 month high of $222.00.

About Propanc Biopharma

Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.